Dr Eric Shiozaki

Partner DCVC Bio


Eric is a Partner at DCVC Bio. Previously, he spent six years as a Partner at Novo Ventures focused on late stage private investments and “crossover” investments in public equities of biotech and medtech companies. Before Novo Ventures, Eric was a Director at Apposite Capital, where he managed the firm’s US office and focused on investing at the growth stage of private companies in biotech. He led numerous successful investments on behalf of Apposite including Ambrx (acquired by WuXi-led consortium), OmniGuide, Ulthera (acquired by Merz), Wellpartner (acquired by CVS), Xthetix (acquired by Amway) and Zonare (acquired by Mindray). Previously, Eric worked in business development at Vitapath Genetics, he was a member of the investment team at Burrill & Company and he was a licensing associate in the tech transfer office at UCLA. Eric received a BS in Biophysics from Johns Hopkins University and a Ph.D. in Molecular Biology from Princeton University.